Literature DB >> 2184506

Efficacy of fluconazole in experimental invasive aspergillosis.

T F Patterson1, P Miniter, V T Andriole.   

Abstract

The efficacy of fluconazole against Aspergillus fumigatus was evaluated in an immunosuppressed, temporarily leukopenic rabbit model of invasive aspergillosis. Fluconazole was given at a dosage of 60 mg/kg twice daily and was compared with amphotericin B given intravenously at a dosage of 1.5 mg/(kg.d). Fluconazole reduced the tissue burden of Aspergillus from that in untreated controls by 10- to 100-fold in liver, kidney, and lung. However, at these doses amphotericin B was more effective in sterilizing tissues and in reducing the tissue burden of Aspergillus in those organs. Both fluconazole and amphotericin B decreased or eliminated circulating Aspergillus antigen and improved survival over that of untreated controls. Thus fluconazole shows activity in this rabbit model of invasive aspergillosis and should be further evaluated for use in the treatment of this disease.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2184506     DOI: 10.1093/clinids/12.supplement_3.s281

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  7 in total

Review 1.  Antifungal treatment strategy in leukemia patients.

Authors:  T Büchner; N Roos
Journal:  Ann Hematol       Date:  1992-10       Impact factor: 3.673

2.  Comparative efficacy of fluconazole and amphotericin B in the parenteral treatment of experimental paracoccidioidomycosis in the rat.

Authors:  R Martinez; M H Malta; A V Verceze; M R Arantes
Journal:  Mycopathologia       Date:  1999       Impact factor: 2.574

Review 3.  Strategies in prevention of invasive pulmonary aspergillosis in immunosuppressed or neutropenic patients.

Authors:  J Beyer; S Schwartz; V Heinemann; W Siegert
Journal:  Antimicrob Agents Chemother       Date:  1994-05       Impact factor: 5.191

4.  Efficacy of UK-109496, a new azole antifungal agent, in an experimental model of invasive aspergillosis.

Authors:  D George; P Miniter; V T Andriole
Journal:  Antimicrob Agents Chemother       Date:  1996-01       Impact factor: 5.191

5.  T-8581, a new orally and parenterally active triazole antifungal agent: in vitro and in vivo evaluations.

Authors:  A Yotsuji; K Shimizu; H Araki; K Fujimaki; N Nishida; R Hori; N Annen; S Yamamoto; H Hayakawa; H Imaizumi; Y Watanbe; H Narita
Journal:  Antimicrob Agents Chemother       Date:  1997-01       Impact factor: 5.191

6.  Efficacies of two new antifungal agents, the triazole ravuconazole and the echinocandin LY-303366, in an experimental model of invasive aspergillosis.

Authors:  J Roberts; K Schock; S Marino; V T Andriole
Journal:  Antimicrob Agents Chemother       Date:  2000-12       Impact factor: 5.191

Review 7.  Aspergillosis of the CNS in a pediatric liver transplant recipient: case report and review.

Authors:  M Green; E R Wald; A Tzakis; S Todo; T E Starzl
Journal:  Rev Infect Dis       Date:  1991 Jul-Aug
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.